EphA2 T-cell epitope agonists and uses therefore
EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
1. A method of eliciting an immune response to EphA2 in a subject, comprising administering, to the subject, an effective amount of an isolated peptide that consists of 9-35 amino acid residues and wherein said isolated peptide comprises the peptide TLADFDPRV (SEQ ID NO:2, residues 883-891), where said TLADFDPRV (SEQ ID NO:2, residues 883-891) peptide (i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and (ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay.
2. The method of claim 1 , wherein the isolated peptide comprises the peptide TLADFDPRV (SEQ ID NO:2, residues 883-891).
3. The method of claim 1 , where the isolated peptide has one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D.
4. A method of eliciting an immune response to EphA2 in a subject, comprising administering, to the subject, an effective amount of a vaccine formulation comprising an isolated peptide that consists of 9-35 amino acid residues and wherein said isolated peptide comprises the peptide TLADFDPRV (SEQ ID NO:2, residues 883-891), where said TLADFDPRV (SEQ ID NO:2, residues 883-891) peptide (i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and (ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay, and a pharmaceutically acceptable carrier.
5. The method of claim 4 where the isolated peptide comprises the peptide TLADFDPRV (SEQ ID NO:2, residues 883-891).
6. The method of claim 4 , where the isolated peptide has one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D.
7. The method of claim 4 where the vaccine formulation further comprises an adjuvant.
8. The method of claim 5 where the vaccine formulation further comprises an adjuvant.
9. The method of claim 6 where the vaccine formulation further comprises an adjuvant.
10. The method of claim 4 wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.
11. The method of claim 5 wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.
12. The method of claim 6 wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.